Menu
← Oncology Approval Tracker
FDA DECISION ·
Ayvakit
avapritinib · Blueprint Medicines
Open LinkedIn brief ↓1 min read · estimated
APPROVED USE
What FDA approved
Adults with unresectable or metastatic gastrointestinal stromal tumor with a PDGFRA exon 18 mutation, including D842V.
LAMPGEN ANALYSIS
Why it matters
Opened an approved targeted option for a mutation associated with resistance to earlier kinase inhibitors.
What research teams should watch
Build in exon-level genomic reporting and monitor for cognitive adverse effects.
PRIMARY RECORDS